Healthcare
Q32 Bio Inc.(QTTB)
Live Price
Offline$12.64
-0.47% today
1Y Change
+686.27%
Window
Jun 23, 2025 β Jun 8, 2026
- Market Cap
- $60.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +147.3%
- Dividend Yield
- 0.0%
Coverage: 241 bars Β· Jun 23, 2025 β Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Q32 Bio Inc. (QTTB) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $12.64 and up 686.3% across the available one-year price window (Jun 23, 2025 β Jun 8, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +147.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +147.3%, free cash flow +64.3% with operating margin 31.5% and ROIC 29.8%. Valuation is more restrained than many high-expectation growth names at P/E 2.1 and price/sales 1.2. Stock Foundry combines QTTB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Above sector median
+31.5% vs +19.4% peer median
P/E
Below sector median
2.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +147.3%, while operating margin sits near 31.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | β | -1.3% | +14.9% | +141.0% |
2026 Mar 10, 2026 | +529.4% | +15.4% | +2.3% | -8.7% |
2025 Nov 13, 2025 | +56.8% | -2.3% | -12.7% | +33.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QTTB
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
QTTB Max Drawdown
-51.14%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for QTTB and SPY.
Company Overview
Q32 Bio Inc.
NASDAQ Global Market
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiΒinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
- Leadership
- Jodie Pope Morrison
- IPO Date
- Mar 28, 2018
- Employees
- 28
- Street Address
- 830 Winter Street
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 999 0232
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 2.1
- EV/EBITDA
- 1.3
- Price/Sales
- 1.2
- Price/Book
- 1.5
Growth
- Revenue
- 0.0%
- EPS
- +147.3%
- Free Cash Flow
- +64.3%
Profitability
- Gross Margin
- 99.7%
- Operating Margin
- 31.5%
- Net Margin
- 55.5%
- ROE
- 1630.2%
- ROIC
- 29.8%
Balance Sheet
- Debt/Equity
- 0.27
- Current Ratio
- 4.85
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.